A new type of H7N9 subtype avian influenza virus appeared in my country, which is a typical low-pathogenic avian influenza virus. Poultry infected with the virus have no obvious clinical symptoms, and the virus can only replicate in the upper respiratory tract of poultry. However, this new type of H7N9 virus has shown strong pathogenicity to humans. So far, 453 cases of infection have been reported, of which 175 have died, with a case fatality rate of 38.6%. As a low-virulence avian influenza virus, it is the first time that it has shown such high pathogenicity to humans; its pathogenic mechanism has always been the focus of attention by scientists around the world.
Recently, the influenza virus research team of the Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, has made breakthrough progress in the study of the pathogenic mechanism of the H7N9 subtype avian influenza virus. Studies have shown that the PB2, NP, and M genes of the H7N9 virus determine the pathogenicity of the virus to mammals; these three internal genes, together with HA and NA on the surface of the virus, contribute to the virus’s ability to infect human cells; it is also confirmed that the virus is of avian origin Four days after H7N9 virus infects mammals, mutations in key sites of host adaptability will occur, which enables the virus to rapidly achieve cross-species infection from birds to mammals. The virus's virulence to mammals is significantly enhanced, leading to the death of the host.
The research analyzed the molecular pathogenic mechanism of H7N9 virus infecting mammals, laying a foundation for the design of drugs and vaccines for avian influenza virus and the prevention and control of avian influenza epidemics.